A groundbreaking immunotherapy for acute myeloid leukemia (AML) has shown encouraging outcomes in a small clinical trial conducted at Washington University School of Medicine in St. Louis. The study, published in the journal Science Translational Medicine, focuses on enhancing the immune system's natural killer (NK) cells through a laboratory training process to improve their effectiveness against leukemia cells.
In this phase I trial, responses to the treatment were observed in five out of nine evaluable patients, with four achieving complete remission and one achieving partial remission. The treatment involves extracting NK cells from a closely related donor, activating them with a combination of interleukins 12, 15, and 18, and then infusing them into the patient. This process 'trains' the NK cells to more effectively recognize and attack leukemia cells.
Patients in the trial were particularly ill, having exhausted other treatment options, and faced a choice between participating in the clinical trial or entering hospice care. The therapy's safety was established, with patients experiencing only mild side effects, such as low-grade fever. The researchers are now focusing on determining the consistency of patient responses at higher dose levels and exploring combinations with other immunotherapies to further enhance the anticancer response of NK cells.
This innovative approach represents a significant step forward in the treatment of AML, especially for patients with limited options, and opens new avenues for research into the potential of memory-like NK cell therapy in conjunction with other treatment strategies.
